Search research articles
Contact Us
Filters
Showing results (1-10 of 23) with videos related to
Page
of 3
Sort By:
The New England Journal of Medicine
|
November 2, 2022
Teclistamab in Relapsed or Refractory Multiple Myeloma. Reply
Philippe Moreau, Suzette Girgis, Jenna D Goldberg
The AAPS Journal
|
July 25, 2009
Population pharmacodynamic parameter estimation from sparse sampling: effect of sigmoidicity on parameter estimates
Sudhakar M Pai, Suzette Girgis, Vijay K Batra, et al.
The AAPS Journal
|
December 16, 2005
Pharmacodynamic parameter estimation: population size versus number of samples
Suzette Girgis, Sudhakar M Pai, Ihab G Girgis, et al.
Clinical Pharmacology : Advances and Applications
|
January 31, 2012
Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole
Chirag G Patel, Li Li, Suzette Girgis, et al.
Clinical Pharmacokinetics
|
November 18, 2011
Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphoma
Andrzej Hellmann, Simon Rule, Jan Walewski, et al.
Investigational New Drugs
|
December 20, 2022
A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors
Victor Moreno, Ruth Perets, Tamar Peretz-Yablonski, et al.
Epilepsy Research
|
February 25, 2014
Evaluation of JNJ-26489112 in patients with photosensitive epilepsy: a placebo-controlled, exploratory study
Nicholas A Di Prospero, Jay J Gambale, Gahan Pandina, et al.
Targeted Oncology
|
September 16, 2024
Evaluation of Drug-Drug Interaction Potential of Talquetamab, a T-Cell-Redirecting GPRC5D × CD3 Bispecific Antibody, as a Result of Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma in MonumenTAL-1, Using a Physiologically Based Pharmacokinetic Model
Marie-Emilie Willemin, Jue Gong, Brandi W Hilder, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
June 4, 2024
Evaluating drug interaction potential from cytokine release syndrome using a physiologically based pharmacokinetic model: A case study of teclistamab
Marie-Emilie Willemin, Shun Xin Wang Lin, Loeckie De Zwart, et al.
Blood Advances
|
October 25, 2024
Recombinant Erwinia asparaginase (JZP458) in ALL/LBL: complete follow-up of the Children's Oncology Group AALL1931 study
Luke Maese, Mignon L Loh, Mi Rim Choi, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 23) with videos related to
Sort By:
Page
of 3
The New England Journal of Medicine
|
November 2, 2022
Teclistamab in Relapsed or Refractory Multiple Myeloma. Reply
Philippe Moreau, Suzette Girgis, Jenna D Goldberg
The AAPS Journal
|
July 25, 2009
Population pharmacodynamic parameter estimation from sparse sampling: effect of sigmoidicity on parameter estimates
Sudhakar M Pai, Suzette Girgis, Vijay K Batra, et al.
The AAPS Journal
|
December 16, 2005
Pharmacodynamic parameter estimation: population size versus number of samples
Suzette Girgis, Sudhakar M Pai, Ihab G Girgis, et al.
Clinical Pharmacology : Advances and Applications
|
January 31, 2012
Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole
Chirag G Patel, Li Li, Suzette Girgis, et al.
Clinical Pharmacokinetics
|
November 18, 2011
Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphoma
Andrzej Hellmann, Simon Rule, Jan Walewski, et al.
Investigational New Drugs
|
December 20, 2022
A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors
Victor Moreno, Ruth Perets, Tamar Peretz-Yablonski, et al.
Epilepsy Research
|
February 25, 2014
Evaluation of JNJ-26489112 in patients with photosensitive epilepsy: a placebo-controlled, exploratory study
Nicholas A Di Prospero, Jay J Gambale, Gahan Pandina, et al.
Targeted Oncology
|
September 16, 2024
Evaluation of Drug-Drug Interaction Potential of Talquetamab, a T-Cell-Redirecting GPRC5D × CD3 Bispecific Antibody, as a Result of Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma in MonumenTAL-1, Using a Physiologically Based Pharmacokinetic Model
Marie-Emilie Willemin, Jue Gong, Brandi W Hilder, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
June 4, 2024
Evaluating drug interaction potential from cytokine release syndrome using a physiologically based pharmacokinetic model: A case study of teclistamab
Marie-Emilie Willemin, Shun Xin Wang Lin, Loeckie De Zwart, et al.
Blood Advances
|
October 25, 2024
Recombinant Erwinia asparaginase (JZP458) in ALL/LBL: complete follow-up of the Children's Oncology Group AALL1931 study
Luke Maese, Mignon L Loh, Mi Rim Choi, et al.
Page
of 3